Clinical Trials Directory

Trials / Conditions / Castration-Resistant Prostatic Cancer

Castration-Resistant Prostatic Cancer

19 registered clinical trials studyying Castration-Resistant Prostatic Cancer — 5 currently recruiting.

StatusTrialSponsorPhase
RecruitingA Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic C
NCT06863272
Merck Sharp & Dohme LLCPhase 1 / Phase 2
RecruitingA Study of MGC026 in Participants With Advanced Solid Tumors
NCT06242470
MacroGenicsPhase 1
TerminatedA Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and
NCT05551117
MacroGenicsPhase 2
RecruitingStudy of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
NCT05519449
Janux TherapeuticsPhase 1
WithdrawnStudy of NUV-422 in Combination With Enzalutamide in Patients With mCRPC
NCT05191017
Nuvation Bio Inc.Phase 1 / Phase 2
TerminatedBiomarker-driven Intermittent Docetaxel in Metastatic Castration-resistant Prostate Cancer
NCT04918810
Australian and New Zealand Urogenital and Prostate Cancer Trials GroupPhase 2
CompletedA Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors
NCT05293496
MacroGenicsPhase 1
TerminatedNUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid
NCT05252390
Nuvation Bio Inc.Phase 1
RecruitingFatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer
NCT04337580
Wake Forest University Health SciencesPhase 2
TerminatedA Study Evaluating The Safety, Efficacy and Pharmacokinetics Of Ipatasertib In Combination With Atezolizumab A
NCT04404140
Hoffmann-La RochePhase 1
RecruitingThe Bispecific PSMAxCD3 Antibody CC-1 in Patients with Castration Resistant Prostate Carcinoma
NCT04104607
University Hospital TuebingenPhase 1
UnknownPrecise Therapy for mCRPC Patients Through Whole Exome Sequencing(PTtWES)
NCT04126915
Yinghao Sun—
TerminatedSafety and Targeting of Anti-hk2 Antibody in mCRPC
NCT04116164
SpectronRXEARLY_Phase 1
Active Not RecruitingA Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Pre
NCT03748641
Janssen Research & Development, LLCPhase 3
CompletedPembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Def
NCT03248570
University of California, San FranciscoPhase 2
Active Not RecruitingCognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer
NCT03016741
Northwestern UniversityPhase 4
UnknownProspective REgistry of Targeted RadionucLide TherapY in Patients With mCRPC (REALITY Study)
NCT04833517
Universität des Saarlandes—
CompletedPain Evaluation in Radium-223 Treated Castration Resistant Prostate Cancer Patients With Bone Metastases
NCT02398526
Bayer—
Temporarily Not AvailableExpanded Access Treatment with [Lu-177]-PNT2002 for Adult Patients with Prostate-Specific Membrane Antigen (PS
NCT06033001
Lantheus Medical Imaging—